US interchangeability requirements would be waived for US Food and Drug Administration-approved biosimilar insulins under the Biosimilar Insulin Access Bill that has just been introduced by US representative Glenn Grothman.
Grothman said the legislation aimed to “help increase competition in the insulin market, expand availability to affordable insulin products and...